- Conditions
- Age-related Macular Degeneration
- Interventions
- RetnaGene AMD LDT
- Device
- Lead sponsor
- Sequenom, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- San Francisco, California • Lexington, Kentucky • Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 200
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Corticosteroid
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Advanced Age-related Macular Degeneration
- Interventions
- LFG316
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
- Conditions
- AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
- Interventions
- ABBV-RGX-314, Ranibizumab (LUCENTIS®)
- Genetic · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 671 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 89
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- Choroidal Neovascularization, Age-related Macular Degeneration
- Interventions
- hI-con1, ranibizumab, Sham injection
- Biological · Other
- Lead sponsor
- Iconic Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 44 more
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- Health Management Tool (HMT)
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 23
- States / cities
- Beverly Hills, California • Sacramento, California • Torrance, California + 20 more
- Conditions
- Age-Related Macular Degeneration
- Interventions
- AG-013,958
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 30
- States / cities
- Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
- Conditions
- Choroideremia
- Interventions
- BIIB111
- Genetic
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Baltimore, Maryland + 5 more
- Conditions
- Choroideremia, CHM (Choroideremia) Gene Mutations
- Interventions
- AAV2-hCHM
- Biological
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Macular Degeneration
- Interventions
- GW786034, Placebo
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 3
- States / cities
- Minneapolis, Minnesota • Austin, Texas • Tacoma, Washington
- Conditions
- Macular Degeneration
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- GB-102, Aflibercept
- Drug
- Lead sponsor
- Graybug Vision
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more
- Conditions
- Ocular Melanoma, Choroidal Melanoma, Uveal Melanoma
- Interventions
- Not listed
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Small Posterior Choroidal Tumors
- Interventions
- Not listed
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Eye Diseases Hereditary, Retinal Disease, Achromatopsia, Bardet-Biedl Syndrome, Bassen-Kornzweig Syndrome, Batten Disease, Best Disease, Choroidal Dystrophy, Choroideremia, Cone Dystrophy, Cone-Rod Dystrophy, Congenital Stationary Night Blindness, Enhanced S-Cone Syndrome, Fundus Albipunctatus, Goldmann-Favre Syndrome, Gyrate Atrophy, Juvenile Macular Degeneration, Kearns-Sayre Syndrome, Leber Congenital Amaurosis, Refsum Syndrome, Retinitis Pigmentosa, Retinitis Punctata Albescens, Retinoschisis, Rod-Cone Dystrophy, Rod Dystrophy, Rod Monochromacy, Stargardt Disease, Usher Syndrome
- Interventions
- Not listed
- Lead sponsor
- Foundation Fighting Blindness
- Other
- Eligibility
- Not listed
- Enrollment
- 20,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2037
- U.S. locations
- 1
- States / cities
- Columbia, Maryland
- Conditions
- Age-Related Macular Degeneration, Neovascularization, Choroidal
- Interventions
- Not listed
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 73 participants
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Age-Related Macular Degeneration
- Interventions
- E10030, bevacizumab or aflibercept, E10030 sham injection
- Drug
- Lead sponsor
- Ophthotech Corporation
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 645 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 100
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 88 more
- Conditions
- Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
- Interventions
- 4 mg CLS-TA Suprachoriodal Injection, Sham procedure
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Mountain View, California • Fort Lauderdale, Florida + 7 more
- Conditions
- Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
- Interventions
- Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Wet Macular Degeneration
- Interventions
- KSI-301, Aflibercept, Sham Procedure
- Drug · Other
- Lead sponsor
- Kodiak Sciences Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 53 more
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Fluocinolone
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Choroideremia
- Interventions
- 4D-110
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Salt Lake City, Utah
- Conditions
- Age-Related Macular Degeneration, Choroidal Neovascularization
- Interventions
- Not listed
- Lead sponsor
- Michael Abramoff
- Other
- Eligibility
- 45 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Retinal Artery Occlusions, Polypoidal Choroidal Vasculopathy, Retinal Arterial Macroaneurysm, Juxtafoveal Telangiecasia, Central Serous Chorioretinopathy
- Interventions
- Not listed
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 7 Years to 100 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Portland, Oregon